Ginkgo with Vinpocetine
Goals
$9.19 $0.30 per serving
Product analysis
Ginkgo with Vinpocetine brings together two ingredients investigated for cognition, but dependable improvements in focus or everyday mental performance remain uncertain. The incomplete ginkgo composition also makes it harder to compare with specific preparations linked to particular findings.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality40
The ingredient preparations are named, but their relative quality remains uncertain. Incomplete ginkgo composition prevents a confident match to specific preparations.
Ingredient Transparency80
The ingredient amounts and preparations are disclosed, helping with serving comparisons. The ginkgo composition is incomplete, so it cannot be fully matched to other extracts.
Value For Money45
The vinpocetine has middling value in the unit-cost comparison. The ginkgo price comparison is incomplete, leaving value for the combination uncertain.
Customer Satisfaction80
Customer ratings are generally positive across several hundred reviews. The feedback describes satisfaction but does not establish cognitive benefits.
Product Focus62
The two ingredients share a focus on mental performance. Dependable improvements in healthy adults remain uncertain, and the related vision benefits are also unclear.
- Format
Capsule - Container
- 60 Capsule(s)
- Per serving
- $0.30
- Customer rating
- 4.8 · 714 ratings
Goals
Impact
Moderate effect
Vinpocetine · 10 mg
Ginkgo and vinpocetine are relevant to cognitive function, but their evidence is limited for routine productivity. The 80 mg ginkgo and 10 mg vinpocetine serving provides only partial support in the saved assessment, with stronger preparation support for ginkgo.
How this product is rated for Productivity Boost
Ingredient fit79
The relevant ingredient content is focused on the goal. The assessed amounts provide substantial but incomplete support against the saved dose benchmarks.
Goal fit
The relevant ingredient content is focused on the goal.
Dose adequacy
The assessed amounts provide substantial but incomplete support against the saved dose benchmarks.
Pathways10
The strongest contribution relates to synaptic plasticity and neuroprotection, with limited overall support.
Depth
The strongest contribution relates to synaptic plasticity and neuroprotection, with limited overall support.
Breadth
Support remains too limited to provide broad coverage across the assessed mechanisms.
Evidence42
Ginkgo provides the strongest evidence contribution among the assessed ingredients; that does not guarantee a work-performance benefit. Only part of the relevant ingredient content matches studied preparations; Vinpocetine did not receive that match.
Evidence strength
Ginkgo provides the strongest evidence contribution among the assessed ingredients; that does not guarantee a work-performance benefit.
Studied preparation
Only part of the relevant ingredient content matches studied preparations; Vinpocetine did not receive that match.
Formulation logic100
No configured ingredient conflicts were identified in the saved findings. All assessed ingredients reach the saved minimum amount threshold.
Partner coverage
The assessed ingredients can contribute independently or have their required partner.
Conflicts
No configured ingredient conflicts were identified in the saved findings.
Effective doses
All assessed ingredients reach the saved minimum amount threshold.
Vinpocetine Not classified
No linked studies yet.
Impact
High effect
Ginkgo has mixed findings for selected cognitive tasks, without consistent evidence for sustained attention from a generic preparation. Vinpocetine has a cognitive rationale involving cerebral blood flow, but that does not establish reliable focus improvement in healthy adults. Their declared amounts received recognition in the saved findings, while the supplied scientific context limits expectations of immediate benefit.
How this product is rated for Mental Focus
Ingredient fit78
Ginkgo and vinpocetine account for the main saved ingredient findings. Ginkgo and vinpocetine receive partial recognition for their declared amounts; the comparison does not establish a proven effective focus dose.
Goal fit
Ginkgo and vinpocetine provide the main connection to focus; the product’s broader purposes also affect its saved fit.
Dose adequacy
Ginkgo and vinpocetine receive partial recognition for their declared amounts; the comparison does not establish a proven effective focus dose.
Pathways43
The saved findings emphasize brain energy supply. Other evaluated pathways did not reach the coverage requirement.
Depth
The strongest saved pathway finding concerns brain energy supply.
Breadth
Only brain energy supply reached the coverage requirement.
Evidence65
Ginkgo findings are mixed, and vinpocetine does not have established reproducible healthy-adult attention benefits. The saved findings recognize the declared preparation, without establishing that every claimed attention benefit applies to it.
Evidence strength
Ginkgo findings are mixed, and vinpocetine does not have established reproducible healthy-adult attention benefits.
Studied preparation
The saved findings recognize the declared preparation, without establishing that every claimed attention benefit applies to it.
Formulation logic100
The saved findings identify no missing required ingredient partner. No configured conflicts were detected, and the counted ingredients passed the minimum amount threshold.
Partner coverage
The saved findings identify no missing required ingredient partner.
Conflicts
No configured ingredient conflict was detected in the supplied facts. This does not establish overall safety.
Effective doses
All ingredients counted in the saved findings passed its minimum amount threshold; that threshold does not prove clinical effectiveness.
Impact
High effect
Ginkgo and vinpocetine have been investigated for cognition, but the supplied findings do not establish dependable benefit for healthy adults. Ginkgo has not shown prevention of cognitive decline in a large long-term trial. Vinpocetine’s blood-flow rationale and older disease-cohort findings do not establish routine cognitive improvement.
How this product is rated for Brain Health
Ingredient fit81
The relevant ingredients and their declared amounts support the specific roles described here, with the amount findings detailed below.
Goal fit
The relevant ingredients make this a focused formula for the brain-related roles described here.
Dose adequacy
The declared amounts meet the saved amount comparisons to varying degrees, rather than uniformly matching their reference amounts.
Pathways49
The supplied findings link the ingredients to the processes described below; those links are distinct from demonstrated cognitive outcomes.
Depth
The strongest assigned connection is cerebral energy metabolism; this mechanistic connection does not itself establish improved cognition.
Breadth
One listed pathway has meaningful assigned coverage, so the connection is narrow.
Evidence68
The supplied evidence varies by ingredient, preparation and population. The findings below retain those distinctions.
Evidence strength
Vinpocetine leads the saved evidence comparison, with benefits limited to the population and role described in the supplied context.
Studied preparation
The saved comparison recognizes the declared preparations; this does not establish that the product matches every study population or use pattern.
Formulation logic100
The supplied findings identify no unmet partner requirements or assigned conflicts, and the credited ingredients meet the minimum amount threshold.
Partner coverage
The credited ingredients have no unmet partner requirement in the supplied findings; this does not establish an added combination benefit.
Conflicts
No conflict was identified by the supplied checks; this is not a broader safety assessment.
Effective doses
All credited ingredients meet the saved minimum amount threshold, which is a comparison cutoff rather than a proven effective cognitive dose.
Impact
Moderate effect
Whether ginkgo and vinpocetine help everyday vision is unclear. Their proposed connection involves blood flow, but that doesn't show that taking them improves how well you see. Ginkgo's effects can depend on the particular extract, so benefits from a specific preparation can't simply be expected from every ginkgo ingredient.
How this product is rated for Eye Health
Ingredient fit68
Ginkgo's amount is declared, but the particular extract matters when judging what to expect for vision.
Goal fit
Ginkgo and vinpocetine relate to proposed effects on eye circulation.
Dose adequacy
Ginkgo: 80 mg; Vinpocetine: 10 mg.
Pathways18
The proposed connection is blood flow around the eye; a useful effect on everyday vision is uncertain.
Depth
The proposed connection is blood flow around the eye; a useful effect on everyday vision is uncertain.
Breadth
The proposed role is concentrated on eye circulation, rather than macular pigment, focusing muscles or the visual cycle.
Evidence64
Ginkgo's effects depend on preparation and eye condition; a general vision benefit remains uncertain.
Evidence strength
Ginkgo's effects depend on preparation and eye condition; a general vision benefit remains uncertain.
Studied preparation
A matching ginkgo extract matters; the declared amount alone doesn't make different preparations interchangeable.
Formulation logic100
No particular ingredient conflict or missing individual partner is identified. The combination still needs to be understood through each ingredient's actual role.
Partner coverage
No additional ingredient partner is identified as missing for the individual ingredient roles described here.
Conflicts
No particular ingredient conflict is identified for this serving.
Effective doses
Ginkgo: 80 mg; Vinpocetine: 10 mg.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Ginkgo biloba leaf extract (Flavone Glycosides, Terpene Lactones) | 80 mg | |
Vinpocetine (Periwinkle plant) | 10 mg |
Vinpocetine (Periwinkle plant) · 10 mg OverallScore86
Each serving provides 10 mg of vinpocetine, with the amount recorded separately. At the serving price, 10 mg corresponds to about $0.31 of the whole product.
How this ingredient is rated
Active Ingredient Quality & Bioavailability91
Vinpocetine is identified and its amount is recorded; the evaluation recognizes ordinary excipients.
Vinpocetine Identity and Source
Vinpocetine is identified with an amount of 10 mg per serving.
Excipient and Filler Quality
The evaluation recognizes ordinary excipients; that alone does not characterize the entire ingredient list.
Dose, Safety & Label Transparency100
Each serving contains 10 mg of vinpocetine, with its individual amount recorded.
Vinpocetine Dosage Alignment
The recorded vinpocetine amount is 10 mg per serving.
Proprietary Blend Disclosure
The vinpocetine amount is recorded separately, so it can be identified without estimating a blend share.
Value50
The whole-product serving costs about $0.31; the price comparison reflects the vinpocetine amount.
Cost Efficiency per 10mg Dose
At the serving price, 10 mg of vinpocetine corresponds to about $0.31 of the whole product.
Ginkgo (Flavone Glycosides, Terpene Lactones) · 80 mg OverallScore85
Each serving lists 80 mg of ginkgo leaf extract. The extract is described as 24% flavones and 6% terpenes.
How this ingredient is rated
Composition and Label Disclosure70
The ginkgo extract has stated flavone and terpene percentages of 24% and 6%, respectively.
Marker and Preparation Disclosure
The extract is described as 24% flavones and 6% terpenes.
Declared Ginkgolic Acid Limit
No qualifying ginkgolic acid limit is recorded in the saved information, so its level is unknown.
Composition and Label Disclosure100
The selected serving individually lists 80 mg of ginkgo leaf extract.
Individual Preparation Amount Disclosure
The selected serving individually lists 80 mg of ginkgo leaf extract.
Commercial Price and Usability
The whole-product serving costs about $0.31. Price is not evaluated for this ingredient.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis.
- Efficacy of Ginkgo biloba extract EGb 761® in dementia with behavioural and psychological symptoms: A systematic review.
- Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trials.
- Ginkgo biloba extract EGb 761® improves cognition and overall condition after ischemic stroke: Results from a pilot randomized trial.
- Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg.
- Combination of Vinpocetine and Dexamethasone Alleviates Cognitive Impairment in Nasopharyngeal Carcinoma Patients following Radiation Injury.
- Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study.
- Role of sodium channel inhibition in neuroprotection: effect of vinpocetine.
- Effect of vinpocetine (cognitolâ„¢) on cognitive performances of a nigerian population.
- [Study of the effects of vinpocetin on cognitive functions].
- Effect of Ginkgo biloba extracts in the prevention of posterior capsule opacification after cataract surgery: A randomized clinical trial.
- Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma.
- [Ginkgo extract in impaired vision--treatment with special extract EGb 761 of impaired vision due to dry senile macular degeneration].
- Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma.
- [The course of color vision in early diabetic retinopathy treated with Ginkgo biloba extract. A preliminary double-blind versus placebo study].
- [Effect of vasoactive agents on visual functions and ocular blood flow in patients with early manifestations of age-related macular degeneration].
- Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review.
- Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.
- Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.
- Ginkgo biloba extract improved cognitive and neurological functions of acute ischaemic stroke: a randomised controlled trial.